EUVIMEDEUVIMED entdecken
Open Access

Targeting glial metabolism in neurodegenerative diseases: detail matters

Ruqayya Afridi, Kyoungho Suk

Neural Regeneration Research · 2023-11 · 18 (11) · 2393-2394

DOI: 10.4103/1673-5374.371358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neural Regeneration Research, online erschienen am 15.03.2023. Verfasst von Ruqayya Afridi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine; Department of Biomedical Sciences, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine; …. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases, a group of disorders associated with advanced age, are typified by the disease-specific accumulation of mutant proteins and neuroinflammation. For decades, treatment modalities for these disorders have focused on addressing neuronal malfunction, which has resulted in the failure of therapies. Recent studies have identified the crucial role of glial cells in exacerbating neurodegenerative processes via the release of neuroinflammatory mediators. Glia, the major immune component of the central nervous system (CNS), undergo numerous phenotypic transitions and regulate the outcomes of various pathologies (Afridi et al., 2022). Immunometabolism has emerged as a promising field for the fine-tuning of the inflammatory activities of adaptive and innate immune cells by regulating cellular metabolism, and the exploration of the inflammatory activation of macrophages and T-lymphocytes has shown promising results for the treatment of cancer, metabolic syndrome, and various other inflammatory diseases. The idea of regulating the effector functions of a cell by modifying underlying metabolic pathways has recently been adapted in neuroscience. Glial cells are highly plastic in their metabolic machinery and rapidly reprogram their metabolic pathways in a context-dependent manner, for example, to support energetically expensive immune functions in response to inflammatory signals. Metabolic reprogramming is an integral mechanism through which glial cells maintain homeostasis in the CNS. In any acute challenge to the CNS parenchyma, glial cells undergo metabolic reprogramming to counteract the insult and resolve ongoing detrimental processes. However, in diseases with chronic inflammation, metabolic reprogramming often hinders beneficial immune functions of glial cells and exacerbates ongoing neurodegenerative processes. The numerous anomalies in glial metabolic pathways reported in neuroinflammatory and neurodegenerative diseases demonstrate that the complex interplay between inflammation and metabolism must be tightly regulated to support the biological functions of glial cells (Afridi et al., 2022). In preclinical studies, targeting glial metabolism has shown promising effects, which are briefly discussed here. Targeting glial metabolism in neurodegenerative diseases: Glial cells express the full machinery to utilize and process carbohydrates, fatty acids, and amino acids for energy generation. However, they primarily rely on glucose to generate adenosine triphosphate to carry out their cellular activities and provide neurons with metabolic precursors. Various types of metabolic changes have been reported in glial cells in neurodegenerative diseases. The persistent inflammatory environment in these diseases leads to metabolic reprogramming, which increases inflammatory signaling in glial cells. Indeed, the intermediates of glycolytic and fatty acid metabolism can increase signaling along various inflammatory pathways, including mammalian target of rapamycin/hypoxia-inducible factor 1-alpha, mitogen-activated protein kinase, and nuclear factor kappa-light-chain-enhancer of activated B cells (Afridi et al., 2022). Hence, the modulation of glial metabolic reprogramming appears to be a potential strategy to control neuroinflammation and treat these disorders (Figure 1).Figure 1: Metabolic changes in glial cells as therapeutic targets in the treatment of neurodegeneration.ROS: Reactive oxygen species.Microglia: Microglia are the primary immune cells of the CNS and aid the maintenance of brain homeostasis by removing pathogens, misfolded proteins, and cellular debris. Microglial inflammatory activation is involved in the pathogenesis of all major neurodegenerative diseases, and the balance between deleterious and beneficial immune functions of microglia dictates disease progression. In neurodegenerative diseases, microglia lose their immune functions, such as migration and phagocytosis, while the release of neuroinflammatory or neurotoxic cytokines increases. Preclinical and clinical studies have reported the presence of hyperglycolytic microglia in the brains of patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD) as well as in aged brains (Afridi et al., 2022). Microglia derive most of their energy from oxidative phosphorylation (OXPHOS) in a quiescent state and switch to glycolysis whenever the brain microenvironment is challenged. In such instances, increased glycolysis is required to compensate for the ongoing changes and to regulate various microglial immune functions. However, in chronic disease conditions, such as neurodegenerative diseases, persistently enhanced glycolysis is more harmful than helpful, as increased glucose uptake by glycolytic microglia is correlated with neuroinflammation. Increased glycolysis also negatively affects microglial adenosine triphosphate production, leading to the improper functioning of the energetically expensive immune processes of microglia. Various mechanisms through which glycolysis can impede the immune functions of microglia have been identified. Lactate, an end-product of glycolytic metabolism, can modify histones—a phenomenon termed histone lactylation. Increased glycolysis in AD microglia gives rise to a surge in intracellular lactate levels, which in turn, can accelerate the glycolytic rate in a positive feedback manner through histone lactylation (Pan et al., 2022). In addition, increased glycolysis worsens NLR family pyrin domain-containing 3 (NLRP3)-associated inflammation as well as AD pathology. The blockade of glycolysis in the microglia of AD mice by cell-specific deletion of pyruvate kinase M2 has been shown to inhibit the inflammatory activation of microglia and alleviate amyloid beta-associated pathology. Increased levels of hexokinase 2 in microglia have also been reported in AD mouse models and patients (Leng et al., 2022). Increased hexokinase 2 activity in AD microglia drives the cells into an energy-deficient state, impairing phagocytosis. Pharmacological and genetic perturbations of microglial hexokinase 2 increased amyloid beta clearance, reduced neuroinflammation, and improved cognition in AD mice. Persistent low-grade inflammation occurs with increasing age, leading to cognitive decline and the development of neurodegenerative diseases. Chronic microglial activation in the aged brain positively correlated with cognitive decline. The correction of microglial bioenergetic pathways through pharmacological or genetic means in aged mice improved cognitive function (Minhas et al., 2021). Inflammatory microglia found in aged mice revealed an energy-deficient state, which was induced by increased prostaglandin E2 signaling (Minhas et al., 2021). The blockade of prostaglandin E2 signaling restored the microglial energetic state and reduced inflammation, thereby improving cognitive function. The inhibition of microglial glycolysis has also shown promising effects in an animal model of PD (Cheng et al., 2021). Treatment of primary microglial cells with the glycolytic inhibitor 2-Deoxy-D-glucose blocked lipopolysaccharide-induced metabolic reprogramming from glycolysis to OXPHOS, with a concomitant decrease in nuclear factor kappa B signaling, ultimately ameliorating the loss of tyrosine hydroxylase-positive cells in a cell-based model of PD. In addition, the administration of PD mice with 2-deoxy-D-glucose also inhibited microglial inflammatory activation and reduced disease pathology. Chronic exposure of primary microglial cells to α-synuclein preformed fibrils induced several defects in glucose metabolic pathways, rendering them immune-tolerant (Lu et al., 2022). These metabolic defects were coupled with increased generation of reactive oxygen species and reduced phagocytosis. Boosting cellular metabolism with capsaicin, a TRPV1 agonist, restored microglial phagocytosis. Astrocytes: Astrocytes constitute the largest proportion of glia in the brain and provide trophic and metabolic support to neurons throughout their lifespan. They are functionally dynamic cells that display regional and temporal heterogeneities. This structural and functional versatility enables astrocytes to regulate neuronal activity in multiple ways: they regulate neurotransmission by providing metabolic precursors required for the synthesis of neurotransmitters as well as by releasing ions necessary for neuronal electrical activity. In addition, astrocytes play a critical role in neurogenesis, synaptogenesis, and the maintenance of synaptic plasticity. Astrocytes also have immune functions, respond to any instigating stimuli that can endanger brain homeostasis, and undergo morphological and transcriptional changes in a stimulus-dependent manner when the brain tissue is challenged. Diverse phenotypes of reactive astrocytes have been identified in neurodegenerative diseases. The phenotypic transition of astrocytes is strictly dictated by metabolic reprogramming, and reactive astrocytes can therefore be distinguished from homeostatic astrocytes based on their metabolic profiles. Astrocytes exhibit broad alterations in their metabolic pathways regulating carbohydrate and fatty acid synthesis or degradation in AD, PD, Huntington’s disease (HD), and amyotrophic lateral sclerosis. Increased glycolytic rates in neurotoxic astrocytes not only trigger inflammatory signaling but also compromise the provision of metabolites to neurons, leading to neurodegeneration. In in vitro models of AD, PD, and HD, astrocytes displayed impairment in mitochondrial OXPHOS, leading to increased reactive oxygen species generation (Afridi et al., 2022). In addition, astrocytes in the AD model showed poor performance in clearing lipid droplets, thereby making neurons more vulnerable to degeneration. In PD astrocytes, mitochondrial metabolism is altered, leading to the increased expression of major histocompatibility complexes I and II (Russ et al., 2021). Similar findings have been reported in cellular and animal models of amyotrophic lateral sclerosis, in which inflammatory astrocytes exhibited severe mitochondrial deficits coupled with increased inflammatory signaling (Kim et al., 2021). The modulation of the metabolic shift in inflammatory astrocytes has shown promising results in preclinical studies. Deletion of astrocyte-specific apolipoprotein E4 in an animal model of AD increased the proportion of homeostatic astrocytes and enhanced mitochondrial metabolism (Wang et al., 2021). Apolipoprotein E4 deletion also reduced astrocyte activation, as demonstrated by the expression of glial fibrillary acidic protein and vimentin. Moreover, the restoration of astrocytic homeostatic functions by apolipoprotein E4 deletion reprogrammed the metabolic profile of inflammatory microglia from glycolysis to OXPHOS in AD mice, thereby reducing AD-like pathology. The targeting of glycolysis in inflammatory astrocytes in HD and amyotrophic lateral sclerosis models has also resulted in disease-modifying effects. Astrocytes harboring the SOD1 G93A mutation displayed increased glycolytic metabolism, and dichloroacetate blocked this effect and reduced neurotoxicity (Miquel et al., 2012). Oligodendrocytes: Oligodendrocytes are another major type of glial cells that provide metabolic and trophic support to neurons. Their main role is to generate myelin to enable the propagation of action potentials. Like microglia and astrocytes, oligodendrocytes undergo profound structural, functional, and metabolic changes under pathological conditions. Various alterations in inherent metabolic pathways have been reported in oligodendrocytes in neurodegenerative diseases. These metabolic changes are linked to increased axonal degeneration and demyelination. In AD, various adenosine triphosphate -generating pathways in oligodendrocytes, including OXPHOS, glycolysis, and ketolysis, are severely affected. In addition, the pathways involved in myelin synthesis are altered in AD and aged mice. Defects in the glycolytic pathway in oligodendrocytes have been shown to increase NLRP3 signaling (Zhang et al., 2020). In addition, alterations in the lipid metabolic pathways in oligodendrocytes were sufficient to initiate AD-like pathology. Cholesterol synthesis pathways were also decreased in oligodendrocytes in HD, with the changes leading to heightened neurodegeneration and behavioral defects in HD mice (Ferrari Bardile et al., 2019). Future perspectives: The current era has witnessed a paradigm shift away from the neurocentric view of the CNS; glia have emerged as equivalent participants in regulating brain homeostasis in health and disease. We now understand that all CNS diseases have a glial component and that treatment modalities targeting neurons may be of no benefit if glia are not taken into account. Therefore, understanding glial responses to diseases is key to unlocking the mysteries underlying the treatment of neurodegenerative diseases. The modulation of glial metabolism to regulate effector functions is an emerging approach that has been exploited in various preclinical models of neurodegenerative diseases and has shown promising results. The neurotoxic phenotype of glial cells is driven by profound changes in metabolic pathways, including carbohydrate and fatty acid metabolism. However, this metabolic reprogramming is not necessarily undesirable, as it may well be an adaptive change in response to internal or external insults. The optimal metabolic pathways for the immune functions of glia are yet to be identified. Future research is, therefore, necessary to assess the interrelationship between glial effector functions and metabolic reprogramming and to better understand the detailed molecular mechanisms regulating the metabolic alterations in glial cells. This will open a new avenue for the glia-based treatment of neurodegenerative diseases. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2017R1A5A2015391, 2020M3E5D9079764) (to KS). C-Editors: Zhao M, Liu WJ, Qiu Y; T-Editor: Jia Y

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine; Department of Biomedical Sciences, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine; Brain Science and Engineering Institute, Kyungpook National University…

Zitieren

APA

Afridi, R., & Suk, K. (2023). Targeting glial metabolism in neurodegenerative diseases: detail matters. Neural Regeneration Research, 18(11), 2393-2394. https://doi.org/10.4103/1673-5374.371358

Vancouver

Afridi R, Suk K. Targeting glial metabolism in neurodegenerative diseases: detail matters. Neural Regeneration Research. 2023;18(11):2393-2394. doi:10.4103/1673-5374.371358

BibTeX
@article{Afridi2023,
  author = {Afridi, Ruqayya and Suk, Kyoungho},
  title = {Targeting glial metabolism in neurodegenerative diseases: detail matters},
  journal = {Neural Regeneration Research},
  year = {2023},
  volume = {18},
  number = {11},
  pages = {2393--2394},
  doi = {10.4103/1673-5374.371358}
}
Kostenlos starten →